No profile data available.
Jade Biosciences, Inc. (JBIO) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Waltham, United States, with about 55 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$127.41 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $915.17 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
Jade Biosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$915.17 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Amphastar Pharmaceuticals, Inc. (AMPH), MannKind Corporation (MNKD), MoonLake Immunotherapeutics (MLTX), Sana Biotechnology, Inc. (SANA).